一级毛片视频免费观看,在线免播放器高清观看,亚洲欧洲中文字幕第一区,亚洲18色成人网站WWW48,久久久推荐一区二区

Industry Dynamics

Industry News

12-15

2020

Novartis receives EU approval for Leqvio?* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year

December 22, 2020 — Novartis announced today that the European Commission (EC) has approved Leqvio?* (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. This approval is based on the……

11-25

2020

FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies

November 20, 2020 -- Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing……

11-09

2020

Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack

November 06, 2020 –AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institu……

10-30

2020

FDA Approves Expanded Indication for Merck’s KEYTRUDA? (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)

October 25, 2020 -- MSD, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-2 therapy, as monotherapy for the treatment of adult patients with re……

10-09

2020

Kyowa Kirin Announces European Commission (EC) Approval of CRYSVITA? (burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults

October 5, 2020 – Kyowa Kirin Co., Ltd. today announced that the European Commission (EC) has approved CRYSVITA? (burosumab) for use in older adolescents and adults with the rare disease X-linked hypophosphataemia (XLH).……

09-29

2020

FDA Approves KALYDECO? (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

September 26, 2020 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO? (ivacaftor) for use in children with cystic fibrosis (CF) ages four ……

< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 >

Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1

一级毛片视频免费观看,在线免播放器高清观看,亚洲欧洲中文字幕第一区,亚洲18色成人网站WWW48,久久久推荐一区二区